Clinical Trials Logo

Keratoconjunctivitis Sicca clinical trials

View clinical trials related to Keratoconjunctivitis Sicca.

Filter by:

NCT ID: NCT06119386 Completed - Dry Eye Clinical Trials

Quantum Molecular Resonance Electrotherapy in Severe Dry Eye Disease

QMR
Start date: November 3, 2022
Phase: N/A
Study type: Interventional

To evaluate the efficacy and safety of Quantum Molecular Resonance (QMR) treatment in patients with severe dry eye disease (DED), as well as its effects on aqueous-deficient (ADDE), evaporative (EDE) and mixed (MDE) dry eye.

NCT ID: NCT06071780 Completed - Dry Eyes Clinical Trials

Virgin Coconut Oil Contact Lens as Ocular Rewetting Agent

VCOCL
Start date: January 15, 2019
Phase: N/A
Study type: Interventional

This is a clinical trial where 44 subjects dry eyes were instilled with Virgin Coconut Oil (VCO CL) using contact lenses as its vehicle. All subjects are healthy subjects with no other ocular diseases except for having some dry eye symptoms (included with McMonnies questionnaires). Parameters measured at baseline and after 15 minutes of insertion and were compared. The control eyes were inserted with contact lenses soaked in saline (CCL). The eye that wears the VCO CL or the CCL were chosen randomly by masked operator. At the end of this study, the parameters measured will indicate if the VCO CL was able to retain tears in the eye and remove the dry eyes symptoms.

NCT ID: NCT06058559 Completed - Dry Eye Disease Clinical Trials

Effect of Sunflower Lecithin Supplementation on Meibomian Gland Function in Adults With Dry Eye Disease

Start date: June 20, 2023
Phase: N/A
Study type: Interventional

This prospective study will evaluate the effect of oral sunflower lecithin dietary supplementation on meibomian gland function in adults with dry eye disease.

NCT ID: NCT06018571 Completed - Dry Eye Disease Clinical Trials

Burden of Illness and Treatment Assessment of Patients With Dry Eye Disease: A Cross-Sectional Survey of Real-World Patients With Dry Eye Disease in the US

Start date: June 2, 2022
Phase:
Study type: Observational

This study employed secondary database analysis of the Adelphi Dry Eye Disease (DED) Disease Specific Programme™ (DSP™), a templatized cross-sectional survey with retrospective data collection that is administered by Adelphi to a convenience sample of patients diagnosed with DED, and their consulting physicians in the United States. In addition to the survey data, the DED DSP also included recorded medical history data as reported by physicians (optometrists, ophthalmologists or refractive surgeons).

NCT ID: NCT06013436 Completed - Dry Eye Clinical Trials

AST Combined With 0.05% Cyclosporin Eye Drop Improve Corneal Nerve Density in Patients With SS Dry Eye

AST/SS
Start date: June 1, 2022
Phase:
Study type: Observational

The objective of the present study was to evaluate the efficacy of autologous serum tears combined with 0.05% cyclosporin eye drop in treating Sjögren's syndrome dry eye and their effect on corneal nerves. We assessed the impact of 12-week AST combined with 0.05% cyclosporin eye drop treatment on signs, symptoms, and sub-basal nerve density (SND) in patients with dry eyes related to Sjogren's syndrome.

NCT ID: NCT05931861 Completed - Dry Eye Clinical Trials

Performance and Safety Assessment of T2769 in Contact Lens Wearers With Dry Eye Symptoms.

Start date: August 15, 2023
Phase: N/A
Study type: Interventional

This is a confirmatory clinical investigation. The objective is to collect new additional clinical data demonstrating the safety and performance of the device in the contact-lens wearing population with dry eyes. The hypotheses are that T2769 improves dry eye symptomatology (e.g. decrease in CLDEQ-8 score, in OSDI score, ocular discomfort assessed by VAS) and signs (e.g. increase in Schirmer and TBUT, decrease in Oxford score) at D36, in comparison to baseline. The primary objective of this investigation is to assess the performance of T2769 in contact lens wearers with dry eye symptoms in terms of change from baseline (Day 1) to Day 36 (Final visit) in Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) total score.

NCT ID: NCT05918406 Completed - Dry Eye Clinical Trials

Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya

Start date: June 14, 2023
Phase: Phase 4
Study type: Interventional

The objective of this study is to determine the safety of the nasal guide when utilized to aid in the administration of Tyrvaya (varenicline solution 0.03mg) Nasal Spray

NCT ID: NCT05911555 Completed - Dry Eye Clinical Trials

Mucin Levels in Dry Eye and Normal Populations

Start date: May 2013
Phase:
Study type: Observational

The purpose of this study is to evaluate changes in ocular mucin levels in response to a drying environment in subjects with dry eye disease as well as patients who report no history of dry eye disease. It is expected that exposure to the dry environment will alter mucin levels in different ways when comparing the two groups.

NCT ID: NCT05888519 Completed - Dry Eye Disease Clinical Trials

Evaluation of Safety and Tolerability of Investigational Ocular Lubricants

Start date: July 24, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate investigational ocular lubricants for their safety and tolerability on subjects with mild to moderate dry eye disease.

NCT ID: NCT05878067 Completed - Dry Eye Syndrome Clinical Trials

A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants

Start date: June 27, 2023
Phase: Phase 3
Study type: Interventional

Dry Eye Disease (DED) is a condition where the tear film of the eye becomes unstable and along with ocular surface inflammation and damage leads to inadequate tear production and eye lubrication. This study will evaluate symptom relief and tolerability of ABBV-444 eye drops in adult participants. ABBV-444 is being developed for the treatment of Dry Eye Disease (DED). This is a 30-day, open-label study to evaluate adult participant symptoms and tolerability of ABBV-444. Around 40 participants will be enrolled in 1 site in the United States. Participants will receive 1-2 drops of ABBV-444 in each eye as needed but minimally twice a day for 30 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.